The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Lamki, Rafia S., Hudson, Nicholas J., Bradley, John R., Warren, Anne Y., Eisen, Tim, Welsh, Sarah J., Riddick, Antony C. P., O’Mahony, Fiach C., Turnbull, Arran, Powles, Thomas, Reverter, Antonio, Harrison, David J., Stewart, Grant D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236799/
https://www.ncbi.nlm.nih.gov/pubmed/32272660
http://dx.doi.org/10.3390/biology9040074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236799/
https://www.ncbi.nlm.nih.gov/pubmed/32272660
http://dx.doi.org/10.3390/biology9040074

Ejemplares similares